Attorneys general from New York, California, Massachusetts, and New Jersey have petitioned the Food and Drug Administration (FDA) to remove existing restrictions on the abortion pill mifepristone.
FDA Commissioner Marty Makary confirmed that he will review the safety of the abortion drug mifepristone after a study revealed troubling adverse health outcomes exceeding the risks reported on its label.
A recent analysis indicates that over 5% of women who took mifepristone for abortion required a second procedure within 45 days, highlighting potential issues with the pill's effectiveness.
The Illinois House of Representatives, led by Democrats, has passed House Bill 3637, aiming to ensure continued access to abortion medication, specifically mifepristone, regardless of potential federal restrictions.
